Riccardo Perfetti - Jul 13, 2021 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role: Chief Medical Officer
Signature: /s/ Shoshana Shendelman, Attorney-in-Fact
Stock symbol: APLT
Transactions as of: Jul 13, 2021
Transactions value $: -$27,536
Form type: 4
Date filed: 7/15/2021, 09:27 PM
Previous filing: Jun 30, 2021
Next filing: Jul 29, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLT	Common Stock	Options Exercise	$662	+460		$1.44	460	Jul 13, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$9.78K	-460	-100%	$21.25^*	0	Jul 13, 2021	Direct	F2, F3
transaction	APLT	Common Stock	Options Exercise	-$662	-460	-50%	$1.44	460	Jul 14, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$9.43K	-460	-100%	$20.51^*	0	Jul 14, 2021	Direct	F2, F4
transaction	APLT	Common Stock	Options Exercise	$662	+460		$1.44	460	Jul 15, 2021	Direct	F1
transaction	APLT	Common Stock	Sale	-$8.99K	-460	-100%	$19.54^*	0	Jul 15, 2021	Direct	F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.28%	$0.00	165K	Jul 13, 2021	Common Stock	460	$1.44	Direct	F1, F6
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.28%	$0.00	164K	Jul 14, 2021	Common Stock	460	$1.44	Direct	F1, F6
transaction	APLT	Stock Option (Right to Buy)	Options Exercise	$0	-460	-0.28%	$0.00	164K	Jul 15, 2021	Common Stock	460	$1.44	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2	Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3	Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.8200 to $21.4850 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4	Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1300 to $20.6850 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3500 to $19.7650 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6	Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.